Construction of CAR-T cells blocking the PD-1/PD-L1 pathway by short-hair RNA gene silencing technology (shRNA) for the treatment of lymphoma (CD19 antigen-expressing) and prostate (PSCA antigen-expressing) mice with subcutaneous xenografts showed remarkably longer survival time and reduced tumor volumes (65). This evidence concerns the gene CD274 and neoplasm.